1.190USDMkt Cap: 2.78M USDP/E: —Last update: 2026-05-22
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap2.78M USD
Enterprise Value-6.45M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.88M USD
Revenue/Share—
Last Price1.190 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.51
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.17
EPS (TTM)-29.01
EPS (Forward)-0.88
52W Range
1.1900% of range1.340
52W High1.340 USD
52W Low1.190 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE1012.50%
ROA-459.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.52M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-118.54%
Net Debt-9.55M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-0.53
Current Ratio1.79
Quick Ratio1.76
Book Value/Sh7.616 USD
Cash/Share4.402 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 21, 2019
Splits
Last Split1:3
Split DateMar 10, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.33M
Float2.12M
Insiders4.31%
Institutions12.10%
Short Interest
Short Ratio0.0d
Short % Float6.67%
Short % Out.6.66%
Shares Short62.52K
Short (prev mo.)472.91K
Technical
SMA 504.614 (-74.2%)
SMA 2008.944 (-86.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)322.96K
Avg Vol (10d)1.09M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—